Inflammatory immune cells predict survival, relapse in MM, WashU-led study finds

FDA accepts NDA for iberdomide in patients with r/r MM

FDA accepted a New Drug Application for iberdomide combined with standard treatment, daratumumab + dexamethasone, (also called IberDd )in patients with relapsed or refractory multiple myeloma. Iberdomide is part of an investigational, new class of medicines called cereblon E3 ligase modulator agents. FDA has granted a Prescription Drug User Fee Act date of Aug. 17 for this indication.

February 20, 2026

Vol.52 No.07

Drugs & Targets

FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM

FDA has approved Darzalez Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Tecvayli monotherapy demonstrates superior PFS and OS vs. standard of care in MM

Johnson & Johnson announced positive topline results from the investigational phase III MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide.

January 16, 2026

Vol.52 No.02

Obituary

Patient advocate David Mitchell, 75, dies of multiple myeloma

David Mitchell, a tireless patient advocate whose lived experience with multiple myeloma shaped a decade of courageous leadership on behalf of patients nationwide, died Jan. 2. He was 75.

January 09, 2026

Vol.52 No.1

By Ellen V. Sigal

Clinical Trials & Tribulations

Smoldering multiple myeloma: Rethinking the waiting game

With the recent FDA approval of daratumumab for high-risk smoldering multiple myeloma, the moment is ripe to revisit the evolution of our understanding of smoldering multiple myeloma. This development not only underscores the growing recognition of early intervention but also invites a broader reflection on the biological insights and therapeutic strategies that have shaped—and continue to shape—this transitional disease state.

November 14, 2025

Vol.51 No.42

By C. Ola Landgren